Boston Scientific Corporation Spinal Cord Stimulator

The Boston Scientific Spinal Cord Stimulator litigation was centralized in June 2026 before Judge Josephine L. Staton in the Central District of California, consolidating claims that implanted spinal cord stimulator devices caused injury through lead migration, device malfunction, infection, or the need for revision surgery in patients originally implanted to manage chronic pain. With all 29 total actions filed still pending as of the JPML's September 2026 report, this is a docket in its earliest organizational phase — no bellwether cases have been selected, no general-causation record exists yet, and claim volume is still small relative to how implanted-device mass torts typically develop once plaintiff-firm case identification ramps up.

At this stage, funding decisions rest on individual claim strength rather than docket-wide outcome data: implant date, device model, the nature of the device-related complication, and whether revision surgery was required are the diligence items that matter most, since there is no settlement program or bellwether verdict to use as a pricing anchor. Spinal cord stimulator claims typically carry a substantial medical-lien profile — implantation, explantation, and revision surgeries are expensive procedures, and insurers and providers will have real claims against any eventual recovery, so lien exposure should be modeled early rather than assumed away.

For a firm beginning to build a spinal-cord-stimulator inventory, portfolio finance is available but should be structured for a longer expected duration than a mature docket would require, given how early this proceeding is in its life cycle. Criterica Capital's mass tort finance product is the relevant path for claims tied to this litigation as it develops, and a structural brief on the docket is available through Criterica Intelligence.

Pre-settlement funding is a non-recourse purchase of a portion of the proceeds of a pending legal claim — not a loan. If the case does not result in a recovery, nothing is owed. Rates, fees, and repayment terms are disclosed in full in the funding agreement, which the applicant’s attorney reviews before signing. Availability and terms vary by state.